Insider transaction details
John David Finley, Palisade Bio, Inc.'s chief executive officer and chief financial officer, sold 3,896 shares of the company's common stock on February 12, 2026, at a per-share price of $1.75, according to a Form 4 filed with the Securities and Exchange Commission. The sale generated proceeds totaling $6,818.
The same filing reports that on February 11, 2026, Finley was issued 13,333 shares of common stock pursuant to the settlement of vested restricted stock units that had been granted on February 11, 2025. In addition, Finley exercised options on 13,333 restricted stock units at a price of $0.
Following these documented transactions, Finley directly holds 27,353 shares of Palisade Bio common stock and has an indirect holding of 51 shares through FCW Investments, LLC.
Company developments highlighted in the filing and recent disclosures
Palisade Bio also disclosed a set of corporate developments that relate to its lead candidate, PALI-2108. The Crohn's & Colitis Foundation approved a strategic equity investment of up to $500,000 expressly to support the clinical development of PALI-2108, which the company is advancing for fibrostenotic Crohn's disease and ulcerative colitis.
The company secured a composition-of-matter patent for PALI-2108 in Japan; the patent provides protection through 2041. Palisade Bio has further strengthened its clinical advisory resources by appointing two inflammatory bowel disease specialists, Laurent Peyrin-Biroulet, MD, PhD, and David T. Rubin, MD, to its Clinical Advisory Board.
Analyst coverage was initiated by both B.Riley and Clear Street, each assigning a Buy rating. B.Riley set a price target of $7.00, while Clear Street established a $12.00 target. Both firms cited the clinical data for PALI-2108 as a basis for their coverage. Palisade Bio has indicated plans to advance PALI-2108 toward Phase 2 development for ulcerative colitis and fibrostenotic Crohn's disease.
Context and implications
The Form 4 filing documents both the issuance of vested RSUs and a subsequent partial sale of shares by the principal executive and financial officer of the company. The corporate announcements referenced in the filing outline financing, intellectual property, clinical development pathway and advisory appointments related to the company's lead investigational product.
All figures, dates and names referenced in this report are taken from the company filings and disclosures cited in the Form 4 and accompanying corporate statements.